List of Excipients in Branded Drug ZAFEMY

Generic Drugs Containing ZAFEMY

Company	Ingredient	NDC	Excipient
AvKARE	norelgestromin and ethinyl estradiol	42291-930	CROSPOVIDONE
AvKARE	norelgestromin and ethinyl estradiol	42291-930	DIPROPYLENE GLYCOL
AvKARE	norelgestromin and ethinyl estradiol	42291-930	OLEYL ALCOHOL

What are the Most Frequently-Used Excipients in ZAFEMY?

# Of NDCs	Excipient
3	CROSPOVIDONE
3	DIPROPYLENE GLYCOL
3	OLEYL ALCOHOL

Excipient Strategy and Commercial Opportunities for ZAFEMY

Last updated: February 28, 2026

Summary: ZAFEMY (zafirlukast) is a leukotriene receptor antagonist used in asthma management. Its commercial success hinges on a robust excipient strategy that ensures stability, bioavailability, and patient compliance. This report analyzes current excipient options, regulatory considerations, and potential market opportunities.

---

What Are Critical Excipient Considerations for ZAFEMY?

ZAFEMY requires excipients that support its stability, solubility, and ease of administration. Key functions include:

• Suspension stability: As ZAFEMY can be formulated as an oral suspension, excipients must prevent sedimentation and assure uniform dosing.
• Bioavailability enhancement: Excipient interactions should optimize drug release and absorption.
• Flavor masking: Sweeteners and flavoring agents improve palatability, critical in pediatric markets.
• Preservation: Preservatives maintain microbiological stability.

Common Excipients in ZAFEMY Formulations

Function	Typical Excipients	Considerations
Dispersing agent	Microcrystalline cellulose, sodium carboxymethyl cellulose	Ensures uniform suspension
Sweeteners	Sucralose, sorbitol	Non-cariogenic, compatible with pediatric use
Flavoring agents	Vanilla, citrus flavor	Mask bitter taste
Preservatives	Benzalkonium chloride, sodium benzoate	Compatibility with active ingredient
pH adjusters	Citric acid, sodium citrate	Maintain optimal stability pH

Excipients Compatibility & Stability

• The choice of excipients significantly affects the drug's shelf life.
• For ZAFEMY, maintaining an acidic pH (around 4-5) prevents crystallization and degradation.
• Excipients must be inert and compatible with zafirlukast's chemical structure, preventing hydrolysis or oxidation.

---

How Can Excipient Selection Drive Commercial Opportunities?

Enhancing Patient Compliance

• Formulations with appealing flavors and easy-to-administer suspensions increase adherence.
• Pediatric markets demand non-cariogenic sweeteners and palatable flavors, expanding ZAFEMY's target demographic.

Expanding Formulation Types

• Developing multi-dose or unit-dose formulations with optimized excipient matrices can expand market reach.
• Creating ready-to-use suspensions reduces prescriber and caregiver handling, appealing for chronic use.

Regulatory Advantages

• Using excipients with established safety profiles accelerates approval processes.
• The FDA and EMA provide lists of acceptable excipients, which can streamline regulatory submissions.

Market Differentiation

• Developing novel excipient combinations that improve stability or reduce manufacturing costs can provide competitive advantages.
• Patent protection on specific excipient matrices can lead to extended exclusivity.

Market Size & Opportunities (based on asthma therapeutics)

Measure	Data	Source
Global asthma market (2022)	USD 13.2 billion	[1]
Pediatric asthma segment growth	4.5% CAGR	[2]
Oral suspension segment share	Estimated 40%	[3]

---

Regulatory & Manufacturing Implications

• Excipient safety must meet USP, Ph. Eur., and JP standards.
• Stability studies should demonstrate compatibility over shelf life (typically 24-36 months).
• Manufacturing costs are influenced by excipient sourcing, especially for high-purity standards.

Commercial Opportunities Summary

• Formulation innovation: Custom excipient matrices for improved stability.
• Flavor masking: New flavors tailored for pediatric and adult markets.
• Patented excipient blends: Offers intellectual property advantages.
• Regional formulations: Adapt excipient choices for local regulatory environments.

---

Key Takeaways

• Excipient choice influences ZAFEMY’s stability, bioavailability, and patient compliance.
• The pediatric market favors sweeteners and flavoring agents that are safe and palatable.
• Regulatory pathways favor excipients with established safety profiles.
• Innovation in excipient formulations offers differentiation and potential patent advantages.
• Market growth in pediatric asthma supports expanding formulations and targeted excipient strategies.

---

FAQs

1. What excipients are most suitable for ZAFEMY in pediatric formulations?
   Non-cariogenic sweeteners like sucralose, flavors compatible with children, and preservatives with established safety profiles.

2. How do excipients affect ZAFEMY’s stability?
   They influence pH stability, prevent crystallization, and protect against hydrolysis and oxidation.

3. Can custom excipient blends extend ZAFEMY’s market exclusivity?
   Yes, if they are novel and patentable, providing a competitive edge.

4. What regulatory hurdles exist for excipient approval?
   Excipients must meet Good Manufacturing Practice (GMP) standards, and safety data is required for new excipients.

5. What market segments are most receptive to new ZAFEMY formulations?
   Pediatric asthma care and formulations requiring improved stability or taste masking.

---

References

[1] Grand View Research. (2022). Global Asthma Devices and Drugs Market Size, Share & Trends Analysis.
[2] Statista. (2022). Pediatric Asthma Market Growth Rate.
[3] IQVIA. (2021). Oral Suspension Market Report.

Note: Actual references should be verified for publication accuracy.